FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282968172> ?p ?o ?g. }

• W4282968172 endingPage "LB080" @default.
• W4282968172 startingPage "LB080" @default.
• W4282968172 abstract "Abstract Purpose: Drug-tolerant “dormant” cells (DTC) have emerged as one of the major non-genetic mechanisms driving resistance to targeted therapy in lung cancer, although the sequence of events leading to entry and exit from dormancy remain poorly described. Here, we provide a step-by-step phenotypic and molecular characterization of the different processes involved during the adaptive response to osimertinib using several EGFR-mutated lung cancer models. This strategy led to the identification of a common vulnerability of drug-tolerant cells which could be efficiently and safely targeted by a clinical stage drug. Experimental design: We used the FUCCI (fluorescence ubiquitination cell cycle indicator) system to determine the cell cycle dynamics in real time during the adaptive response to osimertinib in a panel of EGFR-mutated lung cancer cell lines. We performed scRNAseq on untreated and osimertinib-treated G1 and S/G2 sorted cells during early relapse to determine the molecular mechanisms underlying entry and exit from dormancy. We validated our observations in several in vitro and in vivo models as well as in publicly available patient data. Results: FUCCI labelling allowed the identification of a rare population of S/G2 cycling cells (referred to as early escapers) that emerged in the first hours of treatment amongst a majority of stably arrested and progressively dying G1 cells. scRNAseq data revealed that early escapers emerged from a differentiated alveolar type 1 (AT1) phenotype which was invariably associated with an increase in contractile-related gene signatures, F-actin polymerization and Rho/ROCK pathway activation. Using a screen of Rho-pathway inhibitors, we found that tipifarnib, a farnesyltransferase inhibitor (FTi), induced a complete clearance of DTC in vitro. Co-treatment with tipifarnib, a clinically active FTi, safely and durably prevented relapse to osimertinib in a PC9-xenograft model as well as in a PDX model of EGFRL858R/T790M lung cancer for up to 6 months with no evidence of toxicity. Several farnesylated targets were identified in both G1 and S/G2 treated cells, which could explain the high efficiency of tipifarnib in preventing the adaptive response to osimertinib. Finally, we observed that osimertinib + tipifarnib co-treatment completely suppressed the emergence of the AT1 phenotype, prevented mitosis of S/G2-treated cells and increased the apoptotic response through activation of the unfolded protein response (UPR) pathway. Conclusion: Our data strongly support the use of tipifarnib in combination with osimertinib in the clinic to effectively, durably and safely prevent relapse. Citation Format: Sarah Figarol, Célia Delahaye, Rémi Gence, Raghda Asslan, Sandra Pagano, Jacques Colinge, Jean-Philippe Villemin, Antonio Maraver, Isabelle Lajoie-Mazenc, Estelle Clermont, Anne Casanova, Anne Pradines, Julien Mazières, Olivier Calvayrac, Gilles Favre. Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB080." @default.
• W4282968172 created "2022-06-17" @default.
• W4282968172 creator A5003304070 @default.
• W4282968172 creator A5004395508 @default.
• W4282968172 creator A5017992919 @default.
• W4282968172 creator A5020401927 @default.
• W4282968172 creator A5023478309 @default.
• W4282968172 creator A5029758467 @default.
• W4282968172 creator A5034436415 @default.
• W4282968172 creator A5041795619 @default.
• W4282968172 creator A5042784050 @default.
• W4282968172 creator A5055246540 @default.
• W4282968172 creator A5056939361 @default.
• W4282968172 creator A5061151865 @default.
• W4282968172 creator A5061217925 @default.
• W4282968172 creator A5078216058 @default.
• W4282968172 creator A5083669252 @default.
• W4282968172 date "2022-06-15" @default.
• W4282968172 modified "2023-10-18" @default.
• W4282968172 title "Abstract LB080: Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC" @default.
• W4282968172 doi "https://doi.org/10.1158/1538-7445.am2022-lb080" @default.
• W4282968172 hasPublicationYear "2022" @default.
• W4282968172 type Work @default.
• W4282968172 citedByCount "1" @default.
• W4282968172 countsByYear W42829681722023 @default.
• W4282968172 crossrefType "journal-article" @default.
• W4282968172 hasAuthorship W4282968172A5003304070 @default.
• W4282968172 hasAuthorship W4282968172A5004395508 @default.
• W4282968172 hasAuthorship W4282968172A5017992919 @default.
• W4282968172 hasAuthorship W4282968172A5020401927 @default.
• W4282968172 hasAuthorship W4282968172A5023478309 @default.
• W4282968172 hasAuthorship W4282968172A5029758467 @default.
• W4282968172 hasAuthorship W4282968172A5034436415 @default.
• W4282968172 hasAuthorship W4282968172A5041795619 @default.
• W4282968172 hasAuthorship W4282968172A5042784050 @default.
• W4282968172 hasAuthorship W4282968172A5055246540 @default.
• W4282968172 hasAuthorship W4282968172A5056939361 @default.
• W4282968172 hasAuthorship W4282968172A5061151865 @default.
• W4282968172 hasAuthorship W4282968172A5061217925 @default.
• W4282968172 hasAuthorship W4282968172A5078216058 @default.
• W4282968172 hasAuthorship W4282968172A5083669252 @default.
• W4282968172 hasConcept C121608353 @default.
• W4282968172 hasConcept C126322002 @default.
• W4282968172 hasConcept C2776256026 @default.
• W4282968172 hasConcept C2777626846 @default.
• W4282968172 hasConcept C2778087573 @default.
• W4282968172 hasConcept C2779438470 @default.
• W4282968172 hasConcept C2908647359 @default.
• W4282968172 hasConcept C502942594 @default.
• W4282968172 hasConcept C71924100 @default.
• W4282968172 hasConcept C86803240 @default.
• W4282968172 hasConcept C99454951 @default.
• W4282968172 hasConceptScore W4282968172C121608353 @default.
• W4282968172 hasConceptScore W4282968172C126322002 @default.
• W4282968172 hasConceptScore W4282968172C2776256026 @default.
• W4282968172 hasConceptScore W4282968172C2777626846 @default.
• W4282968172 hasConceptScore W4282968172C2778087573 @default.
• W4282968172 hasConceptScore W4282968172C2779438470 @default.
• W4282968172 hasConceptScore W4282968172C2908647359 @default.
• W4282968172 hasConceptScore W4282968172C502942594 @default.
• W4282968172 hasConceptScore W4282968172C71924100 @default.
• W4282968172 hasConceptScore W4282968172C86803240 @default.
• W4282968172 hasConceptScore W4282968172C99454951 @default.
• W4282968172 hasIssue "12_Supplement" @default.
• W4282968172 hasLocation W42829681721 @default.
• W4282968172 hasOpenAccess W4282968172 @default.
• W4282968172 hasPrimaryLocation W42829681721 @default.
• W4282968172 hasRelatedWork W1967103478 @default.
• W4282968172 hasRelatedWork W2032912323 @default.
• W4282968172 hasRelatedWork W2372561159 @default.
• W4282968172 hasRelatedWork W2375344515 @default.
• W4282968172 hasRelatedWork W2390152934 @default.
• W4282968172 hasRelatedWork W2921871143 @default.
• W4282968172 hasRelatedWork W3039972379 @default.
• W4282968172 hasRelatedWork W3134043497 @default.
• W4282968172 hasRelatedWork W4287830487 @default.
• W4282968172 hasRelatedWork W4308323206 @default.
• W4282968172 hasVolume "82" @default.
• W4282968172 isParatext "false" @default.
• W4282968172 isRetracted "false" @default.
• W4282968172 workType "article" @default.